News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The company’s Growth Portfolio delivered $6.2 billion in revenue
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Subscribe To Our Newsletter & Stay Updated
